T he idea that inappropriate or inadequate antimicrobial therapy of infection leads to excess morbidity and patient mortality is intuitive; however, the actual study of outcomes in patients who receive inappropriate antimicrobial therapy has been reported a surprisingly small number of times. The article by Dr. Lujan and colleagues (1) in this issue of Critical Care Medicine adds to this growing literature. In their study, 100 adult patients with bacteremic pneumococcal pneumonia were evaluated to examine the effect of discordant antimicrobial therapydefined as a failure to provide the patient with at least one antimicrobial with in vitro activity against their clinical isolate within 24 hrs of their admission-on patient outcomes, specifically, 28-day mortality.
Similar to other studies of patients with bacteremic pneumococcal pneumonia (2-6), the mortality rate in the authors' study population was considerable (16%). However, this study extends our current knowledge of the disease by demonstrating the effect of antimicrobial resistance and subsequent discordant antimicrobial therapy on patient outcomes. Specifically, receipt of discordant therapy as a result of infection with a resistant Streptococcus pneumoniae isolate resulted in a significantly higher chance of 28-day mortality (odds ratio ϭ 27.3).
Whether penicillin resistance increases mortality in nonmeningeal pneumococcal disease has been an area of controversy. Studies demonstrating excess mortality in patients infected with resistant S. pneumoniae (7, 8) have been counterbalanced by studies failing to find any evidence of excess mortality (3, 9 -12) . Many of these studies have limitations, including small sample sizes, a failure to differentiate between intermediatelevel (minimal inhibitory concentration [MIC] ϭ 0.12-1.0 g/mL) and high-level (MIC Ն 2 g/mL) penicillin resistance, a failure to adjust for severity of illness and patient co-morbidities, and a failure to account for the type of empirical antimicrobial therapy patients received. By clearly delineating MIC cut points for susceptible, intermediate, and resistant S. pneumoniae isolates, using adjustment for patient comorbidities, and clearly identifying specific antimicrobial regimens given to individual patients, Dr. Lujan and colleagues (1) go a long way in redressing limitations present in previous studies, although the small sample size of their study generates some uncertainty about the magnitude of their findings.
That said, a recently published study, which also took account of limitations present in older studies, reached opposite conclusions. Yu et al. (6) found that discordant antimicrobial therapy among 360 patients with bacteremic pneumococcal disease who received monotherapy was only associated with excess mortality when the isolate displayed high-level resistance (MIC Ն 3 g/mL) to cefuroxime. No excess mortality was seen when patients received discordant therapy with penicillins or ceftriaxone. Their findings were unchanged even when deaths within 3 days of initiating treatment were excluded from the analysis, which may not be preventable by even highly active therapy (13) . As with the study by Dr. Lujan and colleagues (1) , the numbers of patients receiving discordant therapy was small (n ϭ 25), and one cannot rule out the possibility of a type II error.
Is there an explanation for this incongruence? Perhaps. It is well known that the dose and dosing interval of an antimicrobial have just as important an effect on the likelihood of clinical success of therapy as the MIC of the infecting organism. Specifically, for beta-lactam drugs, the likelihood of clinical success is maximized when the serum antimicrobial drug concentration is maintained above the infecting organism's MIC for at least 40% to 50% of the dosing interval (14) . Therefore, S. pneumoniae isolates with relative (MIC ϭ 0.12-1.0 g/mL) or even full penicillin resistance (MIC Ն 2 g/mL) may be successfully treated if large enough doses of penicillin are given in frequent enough dosing intervals (15) . It is this phenomenon that likely explains the failure of previous studies to find outcome differences between patients infected with penicillin-resistant and penicillin-sensitive S. pneumoniae isolates and why the National Committee for Clinical Laboratory Standards have recently redefined nonmeningeal breakpoints for S. pneumoniae with various beta-lactam agents (16, 17) . Under these new guidelines, amoxicillin and amoxicillin/clavulanate MIC breakpoints increased from Յ1, 2, and Ն4 g/mL to Յ2, 4, and 8 g/mL, respectively, and MIC breakpoints for cefotaxime/ceftriaxone increased from Յ0.5, 1, and Ն2 g/mL to Յ1, 2, and Ն4 g/mL, respectively. Raising the breakpoints effectively decreases the number of organisms resistant to the antibiotic. For example, using these new breakpoints, rates of amoxicillin and amoxicillin/clavulanate resistance among 329 S. pneumoniae isolates with high levels of resistance to penicillin (MIC Ն 2 g/mL) was only 29% in a recent study (18) .
Close examination of the ten S. pneumoniae isolates from patients receiving discordant therapy in the study by Dr. Lujan and colleagues (1) finds that seven were highly resistant to aminopenicillins (ampicillin and amoxacillin; MIC Ն 8 g/mL) and eight were resistant to macrolides (erythromycin, azithromycin, clarithromycin). It is interesting that eight of ten patients who received discordant therapy were treated with an aminopenicillin or ureidopenicillin (piperacillin, mezlocillin) in doses and intervals that had little chance of achieving serum levels above their infecting organism's MIC for 40% or more of the dosing interval, which, as noted, has been suggested as the minimal amount of time for successful treatment of pneumococci (14, 19) . Only two of 100 isolates examined in this study were resistant to third-generation cephalosporins based on 2002 National Committee for Clinical Laboratory Standards guidelines; however, the ceftriaxone dose given to the individual patient deemed to have received discordant therapy (2 g/24 hrs rather than 1 g/24 hrs) likely resulted in a favorable pharmacokinetic/pharmacodynamic profile. A similar level of detail on individual antibiotic/ MIC combinations was not provided in the study published by Yu et al. (6) , making it impossible to predict the likelihood of therapeutic failure/success based on pharmacokinetic/pharmacodynamic variables.
What do the results of the study by Dr. Lujan and colleagues (1) mean for clinical practice? It is clear from this study and others that the risk of receiving discordant therapy is directly related to the likelihood of being infected with a resistant S. pneumoniae isolate. Multiple studies (6, 10, 12) , including this one, have repeatedly demonstrated that patients who have significant co-morbidities, especially those with an underlying immunocompromised state, and those who have received previous antimicrobials are at the highest risk for infection with resistant S. pneumoniae. It comes as no surprise then that these are the same patients who are most likely to require hospitalization for treatment of their lower respiratory tract infection, which is one of the reasons that published guidelines recommend different empirical antimicrobial regimens depending on underlying patient risk factors and treatment location (20 -23). Most of the subjects who received discordant therapy in the study by Dr. Lujan and colleagues (1) were treated with amoxicillin/clavulanate monotherapy at relatively low doses, perhaps explaining why this study, in contrast to others, found excess mortality associated with discordant therapy. The results of the study by Dr. Lujan and colleagues (1) suggest that using cefotaxime or ceftriaxone (in combination with a macrolide or a fluoroquinolone) for empirical treatment of hospitalized patients with community-acquired pneumonia can reduce the likelihood of discordant therapy and ensure that appropriate pharmacokinetic/pharmacodynamic variables for clinical success are met, although there is no reason to believe that use of higher doses of aminopenicillins in empirical regimens or monotherapy with a respiratory fluoroquinolone would not have a similar effect.
The questions surrounding the apparent disconnect between in vitro antimicrobial resistance and clinical outcomes in patients with pneumococcal pneumonia is not simply answerable by looking at the MIC of the infecting organism. It is also important to take into account the dosage and the dosing interval of the drugs used in empiric regimens for treatment of community-acquired pneumonia. The study by Dr. Lujan and colleagues (1) is an advancement over previous studies in that it provides the reader with this information and gives us a model on which larger studies should be based. Namely, future studies should: 1) define concordance/discordance of antimicrobial therapy based on revised National Committee for Clinical Laboratory Standards criteria, 2) specific information on dosage of antimicrobials used to treat patients and the dosing intervals at which these drugs are given should be provided, and 3) adjustment for the presence of co-morbidities and severity of illness should be performed when assessing therapeutic effect on clinical outcomes. The results of this study and pharmacokinetic/pharmacodynamic work performed by others suggest that the use of aminopenicillins in currently accepted dosing regimens for the empiric treatment of community-acquired pneumonia should be approached with some caution in individuals at high risk for infection with highly resistant strains of S. pneumoniae. In these patients, increasing the dose of the aminopenicillin used or using a third-generation cephalosporin in its2. Kalin M, Ortqvist A, Almela M, et al: Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. Poor outcomes associated with low lipid and lipoprotein levels* I t has been Ͼ75 yrs since the association was made between low cholesterol levels and disease (1) . Subsequently, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein (HDL) cholesterol have been shown to be substantially reduced in patients with many disorders, including infection (2), cancer (3), and critical illness (4). The severity of illness relates to the extent of reduction because lower lipoprotein concentrations have been found in patients with systemic inflammatory response syndrome (SIRS) compared with patients without SIRS (5) .
There is also an awareness of the possible adverse effects of hypolipidemia (6) . In observational studies, low cholesterol levels have been associated with enhanced mortality (7) and with the development of infectious disorders (8) . Poor clinical outcomes have also been associated with low total or HDL cholesterol concentrations in patients with critical illness (9) or burn injury (10) .
In the current issue of Critical Care Medicine, Dr. Chenaud and colleagues (11) present data in patients admitted to a surgical intensive care unit supporting a link between low apolipoprotein A-I concentrations and progression in SIRS criteria. From analysis of 63 subjects, they defined two groups (SIRS exacerbation and SIRS no exacerbation) based on whether progression in SIRS criteria occurred. They found apolipoprotein A-I and HDL cholesterol concentrations to be significantly lower in the SIRS exacerbation group. There were substantial quantitative differences between the SIRS exacerbation and nonexacerbation groups for C-reactive protein (66.9 vs. 9.5 ng/mL, respectively) and interleukin-6 (174 vs. 129 pg/mL, respectively). These differences were not statistically significant, probably due to the small number and heterogeneity of subjects. Blood levels of inflammatory mediators are important and bear on the mechanism for the low cholesterol, apolipoprotein, and lipoprotein concentrations. We have previously shown an inverse correlation between interleukin-6 and apolipoprotein A-I levels in patients in a surgical intensive care unit (9) . Cytokines may be the connection between activity of disease and lipoprotein concentrations because cytokines help regulate apolipoprotein synthesis. Decreased synthesis of apolipoproteins has been demonstrated in hepatic cell lines exposed to tumor necrosis factor-␣, interleukin-1␤, and interleukin-6 (12), and lower lipid levels have been found in humans given cytokines parenterally (13, 14) .
What is the importance of reduced apolipoprotein A-I concentrations in the intensive care unit setting? The authors demonstrate an inhibitory effect of patient serum on monocyte activation by T-cell membranes that correlated with the concentration of apolipoprotein A-I. Therefore, low apolipoprotein A-I levels might not suppress inflammatory responses to stimuli at a time when excessive cell activation is deleterious. This idea is supported by studies using this same in vitro system with apolipoprotein A-I isolated from normal human serum (15) .
The known interaction of lipoproteins, especially HDL, with endotoxin (16) may also be contributing to the outcomes in this study. Of interest was the occurrence of a septic event in 5 of 29 subjects in the SIRS exacerbation group vs. no events in the 34 subjects in the no exacerbation group. HDL, the primary lipoprotein containing apolipoprotein A-I, has been effective in animal and human models for neutralizing endotoxin (17, 18) . Kitchens et al. (19) demonstrated that HDL and other lipoproteins undergo changes during the acute phase that enhance endotoxin binding and neutralization, despite reduction in absolute lipoprotein levels. Nevertheless, more is likely better. Finally, how can all this information be applied to the treatment of acutely ill patients? It is reasonable to consider apolipoprotein A-I concentrations in assessing risk for progression in patients with critical illness. Ultimately, proof of the importance of apolipoprotein A-I, lipoproteins, or lipids in critically ill patients will depend on the ability to alter outcomes by increasing the concentration of the factor of interest. Recombinant apolipoprotein A-I Milano combined with phospholipid in a 1/1 ratio has been administered by infusion to a limited number of patients with coronary artery disease (20) but has not been used for other indications. Human-derived HDL is unlikely to be a good choice for patients because of safety concerns about bloodrelated products. A protein-free, phospholipid-rich emulsion with endotoxin binding capabilities has been developed and is undergoing clinical testing (21).
The importance of apolipoproteins, lipoproteins, and lipids in the acute phase is gradually becoming better appreciated. It is hoped that greater understanding will translate into meaningful advances in the prognosis of patients with critical illness.
Bruce R. Dying in America* T he incidence of acute lung injury/acute respiratory distress syndrome in the intensive care unit (ICU) has been reported to be 75,000 -150,000 per year (1), and the incidence of severe sepsis has been estimated at 383,000 patients per year (2) . From the study by Dr. Angus and colleagues (3), published in this issue of Critical Care Medicine, we now know that the incidence of death in the ICU is 540,000 per year. In a manner of speaking, we could say that death is the most common illness in the ICU. This is important new information for both medical caregivers and the public. It is interesting that attention to the care we give to dying patients in the ICU has only recently been identified as an important, active aspect of therapy in critical care. For many years, end-of-life care was the domain of outpatient and ward medicine. Hospices, both outpatient and inpatient, have become important aspects of medical care. However, the work of Dr. Angus and colleagues (3) now provides a national scale to what is obvious to any clinician who spends significant time in the ICU: managing the process of dying is common in critical care units.
This study is important for several reasons. First, it provides convincing data that dying in the ICU, or shortly after an ICU stay, is a common occurrence. Although it seems obvious to point out how common it is for patients to die in the ICU, it seems shocking to learn that one out of every five Americans will die during, or shortly after, an ICU stay. This is an important message for the public. Despite years of public discussion, and in the face of legislation, most people do not have advance directives or healthcare proxies (4) . Moreover, during end-of-life discussions, it becomes clear that most patients have not communicated their wishes for end-of-life care to their loved ones. Second, the data serve to underscore the importance of recent survey data that demonstrate discontent, on the part of family members whose loved ones die in the ICU, with the care received. Given the large number of Americans who will die after ICU care, dealing with death in the ICU is an issue of great magnitude in healthcare today. In many ways, inadequate end-of-life care, or administering life-sustaining therapies to patients who have asked not to receive them, is an issue of patient safety, no different than that of mismanaging a mechanical ventilator or inadequate management of diabetic ketoacidosis. This is indeed a public health issue of great magnitude. The appreciation of how many Americans die after receiving care in the ICU mandates a commitment to improving the quality of end-of-life care received by these patients. Quality of care at the end of life should be regarded as important as the quality of care offered to patients who are likely to survive. The effect of poor quality of end-of-life care on families of dying patients can have a devastating effect (5) . Unfortunately for the busy ICU caregiver, end-of-life care skills are no more likely to come naturally to dedicated caregivers than are skills for the management of acute respiratory distress syndrome. As with any therapy in the ICU, pursuit of excellence in care for our dying patients requires a pro-active approach to learning. Although it seems as if this is stating the obvious, the truth is that many clinicians still fail to acknowledge the problems involved in caring for patients at the end of life in the ICU. Too often, the important task of communication is delegated to junior house staff or nursing staff. If recent surveys are to be believed, communication with physicians remains a great obstacle to quality end-of-life care in the ICU. If barriers to adequate skills in mechanical ventilation were so consistently identified, clinicians might readily accept the need to update those skills. Yet, the importance of overcoming identified barriers for end-of-life care is not so widely accepted. So much has been written recently about problems with errors in medicine. Questions of patient safety dominate public discussions about health care, and the Leapfrog group was developed, in part, as a response to the Institute of Medicine's report about these errors. Inadequate end-of-life careadministering life-sustaining therapies unwanted by patients-must be seen in this same light. The numbers produced by the data from Dr. Angus and colleagues (3) bring the magnitude of this issue into focus.
An important limitation of the study by Dr. Angus and colleagues (3), which is pointed out by the authors, does bear repeating. The data are national projections from information obtained from six states. As the authors clearly point out, there are considerable regional variations in ICU utilization at the end of life. Therefore, one must be cautious in the generalization of these into a nationwide estimate.
How do we meet this public health need? The first step, of course, is to acknowledge that our own end-of-life skills can improve. Communication skills involve a lifelong learning process. Data suggest that communication with patients and families at the end of life is often misunderstood (6) . Physicians are poorly trained, at best, in communication skills. These skills are the cornerstone of good end-of-life care. Encouraging patients and families to contemplate and share their feelings about life-sustaining therapies is also important for the future of quality end-of-life care. Rather than waiting until after ICU admission, when few patients can participate in medical decision making (7), these discussions should be encouraged to occur during times of health or relative stability in the course of a chronic illness. Not shrinking back from difficult, time-consuming discussions during office visits and noncritical admissions is also important. Providing the appropriate environment for family discussions and regular family meetings, with adequate time for communication, characterizes quality end-oflife care (8) . Although clinicians may not be financially remunerated for some of these discussions, they are essential for quality ICU care. There are relatively simple ways for improving compassionate ICU care. It is time to view end-of-life care as an issue of medical error, patient safety, and an integral part of the overall quality of care received during ICU admission, no different from any other aspect of ICU care. Along with some other recent data demonstrating interventions for improving the quality of end-of-life care in the ICU, the data from Dr. Angus and colleagues (3) provide the basis for a new era in ICU end-of-life care: one in which we move from simple descriptive studies to acknowledging the magnitude of the problem and developing specific, practical interventions aimed at enhancing the quality of care received by dying patients and their loved ones. It is time to move our understanding of the barriers to quality end-of-life care "from the bench to the bedside" and make our care for those dying in the ICU-something that is inevitable for almost 20% of Americans-more humane, compassionate, and of the highest quality.
Mitchell The initial expectation of critical care seemed to be that a hightechnology care plan could do miraclesperhaps even make death optional (2) . But in reality, that care plan led to another population, one composed of patients who were left not alive (in the sense of being capable of enjoying life) and not able to die (because technology temporarily arrested a disease process but did not reverse it) (3).
Critical care decision making is an imprecise process. It takes time to see whether therapy works. Institution of aggressive care gives the patient the benefit of the doubt, but an aggressive approach increases the possibility of dependence on life support (4). Accordingly, it soon became necessary to ponder limiting a critical care plan when a point of diminishing returns was reached (5) . Without such limits, the potential for warehousing warm cadavers looms large (6) .
At one end of the limitation spectrum, care continues aggressively until a predetermined "stop order" is given (7) . These stop orders might be time related or event related: The order might be given when no improvement has occurred within a defined period or when a certain event (such as the onset of respiratory, heart, or renal failure requiring mechanical life support) has occurred. At the other end of the spectrum, resuscitation is completely forgone, and all treatment is directed toward palliation during the inevitable dying process (8) .
In this issue of Critical Care Medicine, Dr. Silvestri and colleagues (9) explore a gray area in the spectrum of limiting life support (10)-namely, the offering of a less invasive, but clearly artificial, life extender to moribund patients whose care extends beyond the point of diminishing returns. Two cohorts with chronic respiratory failure were offered noninvasive ventilation (NIV) devices to temporarily arrest or slow the progress of their disease. In the case of one cohort, do not intubate (DNI) orders had previously been given; the other cohort received "usual" treatment, with the option of endotracheal intubation.
The DNI cohort was older and sicker and had more comorbidities compared with the "usual care" cohort. Predictably, the DNI cohort, even with the presumed advantage of NIV, did more poorly than the other group. Although NIV may have improved quality of life by permitting eating and facilitating sleep and verbal communication, the 1-yr survival rate and the rate of hospital readmission for recurring problems in the group receiving usual care were not much different from the rates among patients with terminal cancer. The authors conclude that the benefits of using NIV to prolong life and decrease complications are overrated and that the option of NIV should be presented in that light to patients desiring it.
Is this a resource allocation issue, an informed consent and autonomy issue, or a palliative care issue? Clearly the authors do not consider this a resource allocation issue. Their data show that NIV does not significantly prolong life, and the authors are willing to provide that fact, as part of informed consent, to patients desiring NIV. The authors respect the patient's autonomy to choose. So, distilled to its essence, this issue appears to be a gray area of palliative care.
The authors state, "We feel that we should not be denying the willing patients NIV therapy even if they have a DNI status." Therefore, the authors seem to be interpreting DNI order as an order permitting all forms of treatment except intubation. But is NIV any different from endotracheal intubation in a practical sense? Except for the presence of a foreign body in the trachea, NIV is essentially the same, in that it uses hardware to achieve an end-stage therapeutic advantage not possible with more conservative methods. Is NIV a realistic palliative measure?
The answer to that question depends on how the provider defines palliation for a specific patient. If the goal is patient comfort during an inevitable (and untreatable) dying process, then not only is NIV of dubious value-it is contraindicated. It will only prolong a dying process that is expected and anticipated. However, if the goal is to aggressively treat the patient who has a predetermined stop order (no intubation or mechanical ventilation), NIV may be of some value as a palliative treatment, to reduce the discomfort of dyspnea, with no expectation of coincidental prolongation of life.
This stratification within the gray area of DNI must be thoughtfully considered by the clinician and accurately portrayed to the patient for NIV to be of value in a comprehensive treatment plan that includes humane end-of-life care. 4 Medical order formatting in the era of patient safety* A lthough patient safety has been a built-in component of medical practice since the words "primum non nocere" where first articulated by Hippocrates, this innovative, yet intuitive, concept failed to hit the mainstream spotlight until the landmark Institute of Medicine report in 1999 (1). This report basically advised physicians, administrators, regulators, and the public of the magnitude and impact of medical errors and their societal cost-up to $50 billion annually in the Unites States in lost income, disability, and increased healthcare costs (2, 3) . This report and its recommendations have triggered an era of "safety climate" and, consequently, a tremendous amount of work and research designed to improve safety and quality of medical care.
In this issue of Critical Care Medicine, Dr. Wasserfallen and colleagues (4) share with journal readers a simple, yet elegant, intervention that increased safe antibiotic prescription practices in two intensive care units in Switzerland. In their study, they observed antibiotic prescription practices at their surgical (SICU) and medical (MICU) intensive care units from February to April 1997 to obtain a baseline rate of safe antibiotic orders when the medical order sheet was loosely formatted. The authors found that only 66% and 48% of orders in the MICU and SICU, respectively, were considered to be safe according to criteria set by the American Society of Hospital Pharmacists. The authors then shared their findings with both units and decided to implement a simple, formatted order sheet in the SICU the following year. In 2000, they performed another audit in both units, finding that safe antibiotic orders increased to 74% in both units at the expense of fewer ambiguous orders and fewer omissions, even when they had no further intervention in the MICU and the SICU did not fully comply with all the required variables.
This article is important because it shows how a simple intervention, such as preprinting an order format with minimum requirements, has a definite effect in safe prescription practices. More importantly, though, it shows that just observing a process and making people aware of it has a positive effect, such as was seen in their MICU, for which no further intervention was done after the initial observational period, yet antibiotic prescription safety improved. Nevertheless, this study has some limitations. The most relevant is the minimalist approach to antibiotic safety when so much more should be considered than the right name or dose, such as the appropriateness of the prescription for a particular patient and infection. There is little value to an appropriately administered antibiotic if the antibiotic was the wrong one to use in the first place or if no antibiotic was warranted at all. Another problem is the relatively short periods of observation (only a couple of months each time), with very large gaps in between. This could affect the study by introducing seasonal or temporal bias.
As the authors state at the end of their article (4), the future of this area most likely rests on informatics and computerized order entry (5, 6) . This is an exciting area of medical information technology, in which expert systems integrated with several drug databases, pharmacy computers, laboratory computers, and patient information will provide both the "edit checks" and "appropriateness checks" required to reach that patient safety state we are all striving to achieve (7, 8) . While we wait for these systems to be available, fully functional, and integrated into our hospitals (9), simple interventions like the one described by Dr. Wasserfallen and colleagues (4), along with good clinical judgment and just being careful when we write orders, should get us (and our patients) through the day.
Luis Mysteries of the drunken lung* A cute lung injury (ALI) and its more severe manifestation, acute respiratory distress syndrome (ARDS), may result from either direct or indirect assault on the alveolar-capillary membrane by any number of mechanisms and pathways. Conceptually, alcoholism would increase the risk of developing acute lung injury/ ARDS by predisposing to known risk factors. For example, alcoholics might be more likely to experience gastric acid aspiration, pneumonia, or trauma. Indeed, chronic alcoholism has emerged as a risk factor for the development of the acute lung injury/ARDS in at least two large, well-controlled epidemiologic studies (1, 2). More importantly, alcoholism remained a significant risk factor after controlling for other known risk factors, such as source of infection or sepsis. Although this predisposition is not yet well understood, decreased alveolar glutathione levels have been measured in otherwise healthy chronic alcoholics (3), suggesting decreased availability of a critical antioxidant resource and perhaps increased susceptibility to molecular threats during inflammation.
A more extensive scientific foundation exists for understanding the pathogenesis of acute lung injury/ARDS in patients with sepsis than with any other risk factor. In sepsis, failure to control local infection can result in widespread engagement of innate immune pathways, with activation of macrophages, up-regulation of endothelial adhesion molecules, and mobilization of neutrophils. Although local endothelial activation is clearly an adaptive response to infection, systemic activation may lead to tissue injury. Adherence of neutrophils to pulmonary capillaries is a function of increased endothelial activation (4) that may promote cellular (endothelial and epithelial) injury as protease and reactive oxygen and nitrogen species are released (5). As neutrophils marginate within pulmonary capillaries, circulating leukopenia may be observed. Resulting endothelial injury can precipitate increased intravascular coagulation when tissue factor is expressed and can increase permeability of the alveolar capillary membrane, leading to pulmonary edema. Abnormal vasoregulation due to the local production of vasoactive molecules further deranges ventilation-perfusion matching. The syndrome of alcoholism, leukopenia, and pneumonia (ALPS) has commonly been associated with ARDS and multiple organ dysfunction.
Selectins are a family of adhesion molecules expressed on endothelial cells (Eselectin), leukocytes (L-selectin), and platelets (P-selectin) (6) . E-selectin expression seems to reflect endothelial activation, as it is up-regulated on the surface of endothelial cells exposed to endotoxin and inflammatory cytokines in vitro. E-selectin is rapidly shed as bioactive soluble E-selectin (sE-selectin). Because sE-selectin is markedly elevated in critically ill patients during sepsis (7) but not trauma (8) , circulating levels are thought to correlate roughly with innate immune activation. However, several additional factors may influence sE-selectin levels, including renal clearance (9), hepatic dysfunction, and even body fat. Although circulating sE-selectin is increased during systemic inflammation, the functional role and prognostic significance of this molecule remain unclear, as elevated sE-selectin levels have been associated with both decreased lung injury (10) and decreased survival (11) in mixed populations of trauma and sepsis patients.
In this issue of Critical Care Medicine, Dr. Burnham and colleagues (12) add another dimension to our understanding of lung injury in alcoholics, with measures of sE-selectin in a series of critically ill patients. Within 3 days of meeting diagnostic criteria for ARDS, circulating and alveolar sE-selectin levels were increased in alcoholic patients compared with controls. These findings suggest increased endothelial activation in alcoholics early during mechanical ventilation for ARDS. In the paradigm described for sepsis, excessive endothelial activation in response to inflammatory stimuli could be another mechanism for increased lung injury in alcoholics. Increased sE-selectin levels have been reported in a subset of otherwise healthy chronic alcoholics (13), suggesting that endothelial activation could predate a defined inflammatory stress in some individuals.
However, conclusions from these observations should be tempered by two important methodologic considerations. First, outcome differences between study groups (eight of ten control patients and four of ten alcoholconsuming patients died) suggest that important inequities in disease distribution and severity might simply be a consequence of the small sample size. Second, other markers of endothelial activation that might have supported the concept that alcoholism augmented endothelial activation, such as circulating von Willebrand factor (14), were not reported. Uncertainty persists about whether the increase in sE-selectin was caused by enhanced expression and shedding or decreased clearance.
Contrary to a popular adage, alcoholics do indeed die. In the end, investigations of differences in the pathogenesis of lung injury in alcoholic and nonalcoholic patients are important, and multiple mechanisms are likely to be revealed. In the mean time, Dr. Burnham and colleagues (12) provide us with an important clue needed to unravel the mystery of the drunken lung.
Stephen One would expect that, given advances in weather forecasting, a medical center could anticipate the arrival of a tropical storm or hurricane 24 -48 hrs in advance. Allison confounded those predictions, first by proving stronger than initial forecasts indicated and second by failing to follow the pattern typical of most storms once they reach mainland. There is little doubt that Hermann performed admirably. With no power, lights, or air conditioning, the hospital staff managed to transfer Ͼ500 patients out of the hospital safely. This meant, among other things, that some patients had to be carried down ten flights of stairs by volunteers using only flashlights to illuminate their way. The staff of the intensive care unit was able to deliver oxygen and maintain ventilation for every patient.
That not a single patient died is a testimony to the superb work of hospital staff and volunteers.
For medical staffs and hospital administrators alike, there are a number of lessons here, many of which Nates (1) has outlined. In light of the Hermann experience, every hospital should reevaluate its emergency power plan. Every intensive care unit should have a contingency plan to provide oxygen and mechanical ventilation. (One is reminded of the polio epidemics of the early 1950s when medical students assumed shifts to ventilate large numbers of patients by hand in Copenhagen and other cities.) It would seem prudent for every hospital to have at least one secure storeroom stocked with flashlights, batteries, working cell phones, and ample supplies of bottled water. This is nowhere more true than hospitals in the potential path of hurricanes on the Gulf Coast and Eastern Seaboard, those on or near fault lines in the West, and those in the Midwest in Tornado Alley.
That said, for all the damage it did, the Hermann flood was a relatively uncomplicated disaster, as disasters go. Without diminishing the efforts of those involved in the flood, it essen-tially amounted to a massive power failure with the expected complication of loss of all internal hospital services. This, then, developed into a triage and evacuation situation. As catastrophic as the flood was, there were no injured patients being brought in, no dead bodies to contend with, no serious communicable disease threat to hospital workers, and no decontamination issues to consider. The next medical center confronting a disaster of similar proportions may not be so lucky.
One of the keys to the Hermann hospital experience with Allison was the demonstration that heroic efforts by individuals could save lives. As part of the country's largest medical center, Hermann had the advantage of hundreds of volunteers, an immeasurable benefit in hospital disaster management. No one should be deluded into thinking that this level of manpower, which other medical centers may not be able to call on in a disaster, can be a substitute for prudent decision making. Hence, the central question for hospital planners in any situation of this magnitude is, "Should the hospital concentrate on maintaining operations or on triage to other facilities?" When floodwaters made that answer obvious at Hermann, the key was early evacuation and cooperation with other medical centers. Perhaps the most important lesson here is that no hospital is an island (in a figurative sense, because it seems Hermann literally was an island). Future articles that describe their experience in disasters should explain what to do when the hospital can no longer function as a self-contained unit. Who decides? How does this person decide? Do other hospitals in the area share a coordinated triage response?
Given the unpredictability inherent in most disasters, preplanning is clearly as important as the response once the worst occurs. Political leaders must work with the hospital in guiding evacuation and coordination with the other medical centers in the community. Disasters such Allison create scenarios where smaller community hospitals may be forced to assume many of the roles and responsibilities of a major medical center. Once the Texas Medical Center was effectively closed, hospitals for hundreds of miles mobilized to meet its needs. Following the storm, Hermann was shut down for over a month and was not completely operational for 2 months, placing an extra workload on many of those hospitals.
Just like Tolstoy's unhappy families in Anna Karenina, all disasters are different in their own way. In the future, medical centers will experience serious internal hospital disasters as a result of floods, earthquakes, tornadoes, and so on. We know these will occur; we just do not know when and where. When they dohappen, hospitals and regional medical centers must work in tandem. Tropical storm Allison reinforced one of medicine's most precious lessons-humility. Given nature's caprices, sophisticated medical knowledge sometimes takes a back seat to the importance of individuals and institutions cooperating together.
Cory Polishing the crystal ball: Improving our understanding of survival in sepsis* E ach day in the intensive care unit we counsel families about outcomes from sepsis. We describe the overall mortality from this disease, the effect the patient's underlying co-morbidities might have on survival, and the likely outcomes based on similar patients we have treated in the past. This process is a dynamic one in which we constantly reevaluate the patient and update the family. We explain how the patient may have surmounted one hurdle but that other factors may still kill him or her. Often, we also describe that although the patient may have survived the initial battle with sepsis, we have done nothing to affect the prognosis from their underlying cancer, chronic obstructive pulmonary disease, or heart failure. At its root, therefore, we intuitively appreciate that survival from sepsis is driven by many variables, some of which are beyond our control. Rarely, if ever, in this discussion, do we offer estimates of survival to families based on specific scoring systems (1-3). Why the aversion to statistically validated scoring tools? These approaches often do not apply to the particular patient in question. More importantly, most of these severity of illness scores are computed at one point in time and do not take into account how the disease process may evolve (1, 2) . Calibrated for predicting outcome on admission, these systems provide limited insight if the patient survives beyond day 3 (4, 5) .
In this issue of Critical Care Medicine, Dr. Kasal and colleagues (6) describe a new approach to understanding outcomes in sepsis that better captures the complicated and fluid nature of this disease. Traditionally, survival analysis relies on a Cox proportional hazard model (7) . Unlike traditional multivariate analysis, a Cox model expressly explores the effect of time and the period of observation on survival. However, a major assumption of a Cox model is that risk factors for death exert a constant effect over time. In other words, if hypotension correlates with mortality, the Cox model assumes that being hypotensive at admission to the intensive care unit is as important a risk factor for death as the presence of hypotension at intensive care unit day 7. Similarly, if the results of a Cox analysis demonstrate that suffering from diabetes increases the chance of death two-fold (a hazard ratio of 2.0), having diabetes doubles your risk for death at admission, day 1, day 7, and so on. Exploring cause of death data from sepsis, though, suggests that this assumption does not hold in sepsis (8 -10) . Early death in sepsis (within the first 72 hrs) predominantly relates to refractory shock. Death beyond day 3 often is related to respiratory failure, whereas later-term mortality seems driven by chronic conditions and nosocomial infection (8 -10) . In short, there seem to be different phases to acute illness, with survival in each period affected by distinct factors. One can also see this pattern in other forms of critical illness, such as trauma, in which a proportion of patients die in the field due to certain types of injuries, whereas causes of death in patients who survive to the hospital are different. The Cox model also fails to account for the survivorship effect. If an individual does not succumb to the initial septic insult, there is, in part, something unique about that person on a certain level that separates him or her from those who die early.
To address these limitations, Dr. Kasal and colleagues (6) applied two alternative survival models to the results of a large, randomized trial in sepsis (6). The first model was a Cox model modified to look at predictors of mortality at discrete time points. This approach has the advantage of allowing one to explore correlates of outcome over different time periods. However, it begs a question: which time periods? Creating Cox models with nonproportional hazards is also cumbersome and time consuming. Their second model was a Gray's model (11) . In a Gray's model, one first determines which variables are nonproportional in their effect. Then one looks over the entire period of observation to compute hazard ratios.
On a theoretical level, when one compares the findings of the various models, the results are intriguing. Many important correlates of outcome do not have proportional effects over time. In other words, what is an important predictor of death at admission is not necessarily what accounts for death after day 3. In fact, among 27 potential factors that Dr. Kasal and colleagues (6) examined, nine in the amended Cox model and four in the Gray's model expressly exerted nonproportional effects. Understanding this relationship provides important insight to and an appreciation of what drives survival in sepsis. This observation further suggests that interventions and clinical trials designed based on the results of traditional survival analysis may be misdirected because they do not take into consideration this phenomenon. Furthermore, reliance on a Gray's model has the advantage of being more consistent with our understanding of the complexities of acute illness. In other words, the central findings of their Gray's model seem biologically plausible. Similarly, if the Gray's model indicated that all risk factors for death had a constant effect over time, we would question whether it was consistent with our clinical observations and wonder if it added anything to our understanding of mortality in sepsis.
On a practical level, the actual results of the Gray's survival analysis help us to understand factors that affect survival in sepsis. First, increasing age in each of the three models is a significant but weak correlate with outcome. Older patients may do worse, but that clearly is driven by the presence of underlying co-morbidities. Second, after day 5, chronic illness exerts a steadily increasing effect on survival. Thus, when we counsel families, we can now better explain that after patients make it over that initial insult, they are in no way in the clear if they have major co-morbid illness. Third, by approximately day 14, neither of the initially strong predictors of mortality (acute hypotension and number of organ failures) provide much explanatory power in terms of post-day 14 survival. Put another way, if an individual survives to day 14, what likely would have killed the patient earlier no longer contributes much to mortality. Therefore, we need to develop interventions that are focused on preventing early and late death in sepsis, and these potential interventions are likely to be different. Finally, much of our understanding of the pathophysiology of sepsis relies on animal models (12) . The results of the Gray's model created by Dr. Kasal and colleagues (6) imply that these animal models will have limited value in explaining survival in sepsis beyond the acute event. Because animals do not have chronic illnesses, 1) purely employing animal models to improve our understanding of sepsis or 2) 
In 1952, Aubaniac (2) described his experiences of puncturing the subclavian vein. Since that time, central venous catheterization has developed to a standard procedure in routine clinical practice. In critical care and emergency medicine, intravascular catheters have become integral to the practice of modern medicine.
However, although central venous catheters make intensive care for critically ill patients possible, they are also associated with serious complications, the most common of which is infection. Intravascular catheters are one of the most common causes of nosocomial bacteremia, and catheter-related bloodstream infection affects Ͼ250,000 patients per year in the United States (3). The use of such devices accounts for an estimated 90% of all nosocomial bloodstream infections (4), and the attributable mortality rate in intensive care patients is an estimated 35% for each infection (5). Because of this, the decision to use central venous catheters must always be made on the basis of a strict risk-benefit assessment, and for each patient the reasons for catheterization must be given careful consideration.
Different guidelines for the prevention of catheter-related infections have been available since the late 1970s (6) . Various techniques to decrease infection risk, such as skin disinfection using different antiseptics, full-barrier precautions during insertion, specialized care teams, disinfection of ports before connecting catheters, antiseptic-impregnated dressings or anti-infective coated catheters, systemic antibiotic prophylaxis, subcutaneous tunneling, and local application of antibiotic ointment, have been tried with varying degrees of success. Despite these prevention efforts, the rate of central venous catheter-related infections, unlike other device-related infections such as catheter-associated urinary tract infections, has not decreased substantially in the past decade and remains an important cause of morbidity and mortality among patients in health care settings (7) . Clearly, exploring the potential of more effective prophylactic procedures to avoid catheter-related infections is still essential.
Prevention of catheter-related infections depends on an accurate knowledge of the two main routes by which intravascular devices become contaminated: the extraand the intraluminal routes. Intraluminal contamination is the consequence of improper handling of the catheter hub at the time of connection and disconnection of the administration set. It is the most common origin of catheter infections after the first week of catheter placement. To prevent this, strict asepsis must be observed in hub and fluid handling.
Extraluminal catheter seeding results from bacterial invasion from the catheter entry site along the external surface of the catheter and leads to bacteremia most often during the week following catheter placement. The main way of preventing this mechanism is appropriate skin disinfection and the adoption of maximal antiseptic barriers at the time of catheter insertion. However, it has been demonstrated that despite rigorous skin disinfection and observance of a strict aseptic technique, viable microorganisms can be transmitted during the insertion of a central venous catheter and can be isolated from the tip of the catheter in about 15% of cases (8) .
To reduce extraluminal catheter-colonization and, by doing so, to also reduce one of two major causes of catheter-related infections, microorganisms on the skin are suppressed by using antiseptic agents before catheter insertion. In the United States and many countries in Europe, povidoneiodine is by far the most commonly used agent for this purpose, whereas in the United Kingdom chlorhexidine gluconate solutions are favored. In this respect, it is obvious why povidone-iodine and chlorhexidine gluconate particularly have been studied extensively (9 -12) , although other antiseptics, like bispyridine octenidine dihydrochloride (in combination with or without phenoxyethanol) or alcohols like 60% iso-propanol and 70% ethanol alone, also might be possible options. An experimental study comparing the efficacy of 0.1% octendine dihydrochloride with 30% 1-propanol and 45% 2-propanol against 74% ethanol with 10% 2-propanol in decontaminating the insertion site of central catheters demonstrated for both solutions significant reduction of skin organisms (13) . Furthermore, the authors concluded that octenidine/propanol appears to be more effective than alcohol (ethanol/ propanol) alone in reducing microflora of the skin at the catheter insertion site over a 24-hr period. This study also reminds us that by combining alcohols with other antiseptics, not only is the rapid reduction of skin microorganisms possible but also a sustained effect in keeping the microorganism count low is achievable.
However, a meta-analysis of six randomized trials comparing several formulations of chlorhexidine gluconate and 10% povidone-iodine in their ability to prevent catheter colonization and, therefore, catheterrelated infection reported superiority of chlorhexidine gluconate (14) . Analyzing this meta-analysis closer, it becomes apparent that only those studies that used alcoholic chlorhexidine gluconate solutions re-sulted in statistically significant reduction of catheter colonization compared with 10% povidone-iodine alone.
Since ethanol, which often is used as a solvent, possesses a potent microbial logreduction factor and therefore high antiseptic activity, the question arises why until now virtually no randomized controlled trials compared the effect of the same antiseptic in aqueous and alcoholic solution, that is, povidone-iodine in alcoholic vs. aqueous solution.
This issue of Critical Care Medicine features an article partly solving the in vitro/in vivo discordance of the fact that even though in vitro studies favor iodine products, chlorhexidine in alcoholic solution seems more efficient than povidone-iodine in aqueous solution in the clinical setting. In their prospective, randomized unitcrossover study, Dr. Parienti and colleagues (15) report a significant reduction of central venous catheter-related colonizations and infections associated with the use of a combination of 70% ethanol and 5% povidone-iodine for skin disinfection and catheter care, compared with 10% povidoneiodine in aqueous solution alone. The authors conclude that alcohol-based iodophors should be preferred for intact and clean skin disinfection before central venous catheterization.
This work contributes important evidence not only that antisepsis itself is important to reduce and control nosocomial infections but also that the use of the most appropriate chemical composition is of utmost interest. The next step now should be vance of this pathologic entity remains controversial. Endomyocardial biopsies were once commonly performed in patients with significant systolic dysfunction and normal coronary arteries. However, the frequency of biopsies has decreased, in large part because the diagnosis of myocarditis does not alter therapy because immunosuppression does not improve the long-term outcome of patients with dilated cardiomyopathy, even "reactive" patients (1), or patients with biopsy-proven myocarditis (2).
It is into this background that an article describing the prevalence and potential causes of eosinophilic myocarditis in a series of 190 heart transplant recipients is published (3). Pathologic evidence of eosinophilic myocarditis was seen in 14 cases (7%). Patients with myocarditis were more likely to be receiving inotropic therapy (93% vs. 56%) and to have a left ventricular assist device (LVAD) im-planted; however, because only two patients received an LVAD, this association remains questionable. Of clinical importance, patients with eosinophilic myocarditis had similar posttransplant survival to patients without eosinophilic myocarditis.
Eosinophilic myocarditis in the explanted heart has been previously reported. Hypersensitivity myocarditis was reported by Gravanis et al. (4) in 15 of 193 (also 7%) explanted hearts, by the Columbia group (5) in 18 of 250 (7.2%) explanted hearts, and by the UCLA group (6) in seven of 288 (2.4%) explanted hearts. Spear (7) reported a higher incidence of eosinophilic myocarditis (seven of 31; 23%) in explanted hearts and hypersensitivity myocarditis was found in eight of 111 (7.2%) explanted hearts at Henry Ford Hospital (8). The incidence of eosinophilic myocarditis in all of these series is higher than the 0.04% to 0.5% incidence in autopsy series (8) . Others have reported fever in association with dobutamine use, which abated on discontinuation of dobutamine and in some cases recurred with dobutamine rechallenge (9, 10). Table 1 shows clinical characteristics of patients with eosinophilic myocarditis in the explanted heart in the series described above. Eosinophilia was common, however, other characteristics suggesting hypersensitivity (rash or pruritus, fever, or a history of other drug allergies) were variably seen.
Defining the cause of peripheral eosinophilia and eosinophilic myocarditis in a patient population, such as that described in the present article (3) and previous literature (4 -8) , that is extremely ill, receiving numerous medications, and at high risk of infection is difficult. Because of the eosinophilic nature of the infiltrate, drug reactions are a prime consideration; however, these patients are exposed to so many medications (up to 49 in the series by Gravanis et al. [4] ) that blaming one medication becomes difficult. In the present series, an association between inotropic therapy and eosinophilic myocarditis was seen, with 13 of the 14 myocarditis patients receiving inotropes (six dobutamine, six dobutamine plus dopamine, and one dopamine alone) (3). A similar association between dobutamine and eosinophilic myocarditis was present in most other case series (5) (6) (7) (8) . Although the duration of inotropic therapy frequently was not specified, Spear (7) found that myocarditis occurred in seven of 13 patients (54%) that had received dobutamine continuously for Ͼ1 month, but in none of nine patients that received dobutamine for Ͻ1 month. The hypothesis that dobutamine (and/or dopamine) is associated with the development of eosinophilic myocarditis is strengthened by the present series in which for two patients receiving dobutamine and one receiving dopamine, tapering or discontinuing the inotrope resulted in a decrease in eosinophilia and/or eosinophilic myocarditis (3) . Whether this can truly be considered a hypersensitivity phenomenon, however, is questionable, because in one case, improvement was noted with a decrease in drug dose, whereas if a hypersensitivity mechanism were responsible, drug discontinuation should have been required for improvement. Also, even if dobutamine is a responsible agent, it remains unclear if the reaction is to dobutamine itself or the diluent, sodium bisulfite, to which drug reactions are known to occur. It is also of note that in a subset of 51 patients in the series by Gravanis et al. (4) for whom data were available, there was no difference between five patients with hypersensitivity myocarditis and 46 patients without it, in regard to the administration of inotropic drugs, antibiotics, or diuretics. Although eosinophilia has been reported with amrinone use (11), eosinophilic myocarditis has not been reported with the phosphodiesterase inhibitor class of inotropes.
The clinical relevance of the pathologic finding of eosinophilic myocarditis described in clinical series (3-8) is difficult to determine because of the degree of illness of the patients and the relatively short followup before transplantation. It might be anticipated that such an inflammatory myocarditis would produce a decline in ventricular function, as has been seen in patients presenting with severe ventricular dysfunction and shock with biopsy-proven acute necrotizing eosinophilic myocarditis (12) . Such myocardial inflammation might also predispose to ventricular arrhythmias. It is hard to ignore that in the present series the degree of myocytolysis correlated with the intensity of eosinophilic infiltration (3). Indeed, in cases of acute necrotizing eosinophilic myocarditis, degranulation of eosinophils has been noted in the peripheral blood and necrotic myocardium (12) and the proteins in these eosinophilic granules are cytotoxic and capable of producing myocardial damage (12) (13) (14) .
What relevance do the present findings (3) and previous case series ( 4 -8) have for the care of critically ill patients? If a patient is receiving inotropic drugs (particularly dobutamine and possibly dopamine) and develops eosinophilia or a fever, it should be considered that the findings are drug related. Because a heart biopsy will frequently not make the diagnosis of myocarditis, even if present, and carries some risk, a biopsy cannot be recommended. If options are available, such as switching to another inotropic agent or implanting an LVAD, they should be considered. If, indeed, eosinophilic myocarditis results in a deterioration of ventricular function or an increased risk of arrhythmias, the findings might be of even more long-term significance in a critical care population in whom cardiac replacement is not planned. How frequently this might occur is presently undefined because pathologic tissue in a series of patients who are not transplant candidates but have received prolonged inotropic therapy is not available. Finally, although the authors of the current study speculate that steroid therapy might be beneficial (3), caution is advised. Steroids increase the risk of infection and diabetes and impair healing, and when immuno- suppressive therapy for biopsy-proven myocarditis was studied in a randomized trial, no clinical benefit was found (2 In this issue of Critical Care Medicine, Dr. Seguin and colleagues (1) present a prospective study on the incidence and determinants of new-onset AF in a general surgical intensive care unit. Not surprisingly, AF was relatively common, affecting 5% of patients. The incidence in clinical practice may be somewhat higher because in the study all patients with permanent pacemakers (who are especially prone to develop AF) were excluded. In addition, patients in AF at time of admission to the unit were also excluded. Patients who developed AF were more critically ill, received higher doses of catecholamines, and experienced more sepsis, shock, and acute renal failure. Intensive care unit and hospital stay and mortality were significantly increased. Through multivariate analysis, the authors identified several risk factors for the development of AF: older age, blunt thoracic trauma, shock, the use of pulmonary artery catheter, and previous treatment with calcium-channel blockers.
Some of the strengths of the study should be noted. The study included a large series of consecutive patients who were continuously monitored. Potential risk factors were prospectively identified and tabulated only if present before arrhythmia development. The multivariate analysis, however, should be interpreted with caution. The relatively low number of end points makes "overfitting" quite possible (2) .
Some of the proposed risk factors deserve additional comment. Septic shock was strongly associated with the development of AF. Unexplained atrial tachyarrhythmias may be an early manifestation of the sepsis syndrome (3). Several research lines suggest that inflammation plays a role in the pathogenesis of AF. In a case-control study, C-reactive protein, a marker of inflammation, was elevated in patients with AF (4). Furthermore, there was a stepwise elevation in C-reactive protein with greater AF burden. In a large cohort of community subjects, baseline C-reactive protein predicted the future risk of AF (5). The intensity of inflammation may also modulate the response to treatment. Among 50 patients with AF of recent onset treated with intravenous amiodarone, elevated C-reactive protein level and an enlarged left atrium were the only multivariate predictors of failure to convert to sinus rhythm (6).
The tissue, cellular, and molecular pathways mediating the association between inflammation and AF are presently unknown. The inflammatory response to surgery may be genetically determined. In patients undergoing cardiac surgery, a common polymorphism in the promoter of the interleukin-6 gene was associated with higher postoperative blood levels of interleukin-6 and fibrinogen and was a powerful independent predictor of postoperative AF (7) . Future research should elucidate if anti-inflammatory strategies, including the use of cytokines antagonists, have antiarrhythmic effects. In a placebo-controlled study, a single postanesthetic induction dose of dexamethasone significantly decreased the incidence of postoperative fever and AF in patients undergoing cardiac surgery (8) .
The finding that the presence of a pulmonary artery catheter was an independent risk factor for AF is intriguing. AF was never observed during catheter insertion, but appeared instead days later. The authors hypothesize that contact of the catheter with the right atrial wall may be arrhythmogenic. This is difficult to reconcile with the body of research showing that AF is predominantly a left atrial arrhythmia. Perhaps the presence of a pulmonary artery catheter acted as a surrogate for a more critically ill patient. It seems premature to add AF to the long list of complications of hemodynamic monitoring with pulmonary artery catheters in the intensive care unit.
Dr. Seguin and colleagues (1) provide little detail regarding the treatment received by their patients. Treatment of AF in the critically ill patient is based on expert opinion and personal experience, as there are few randomized controlled trials (9) . Two nonmutually exclusive strategies are possible: rate control and conversion. Both have significant limitations. Rate control should always be part of the treatment when the ventricular rate is fast. A rapid ventricular rate is the main cause of hemodynamic deterioration during AF. When not contraindicated, intravenous beta-blockers are the drug of choice: they quickly control the ventricular response and also promote conversion (10) . It should be noted that these patients are often hemodynamically unstable and receiving catecholamine infusions before the onset of AF. Thus, the use of intravenous beta-blockers or diltiazem is not feasible. Clinical experience shows that weaning off the inotropic agents (while administering fluids and alpha-agonists if needed to maintain blood pressure) is often successful in controlling the ventricular response and restoring the hemodynamic status. Intravenous amiodarone (11, 12) and high-dose intravenous magnesium (13) produce less hypotension and are useful to slow down the ventricular response and promote late conversion. Conversion of AF can be attempted pharmacologically or with DC cardioversion. Intravenous amiodarone and ibutilide have similar (and relatively low) efficacy (14) . Urgent cardioversion is generally recommended for patients with acute-onset AF and hemodynamic compromise, but this recommendation is supported by very little evidence. In the absence of concomitant treatment with antiarrhythmic drugs, AF is likely to recur soon. A recent prospective study in the surgical intensive care unit in 37 patients with recent onset of atrial tachyarrhythmias showed prompt cardioversion to be of little value due to a low conversion rate and very high early recurrence (15) . Likewise, in a study of 315 patients undergoing electrical cardioversion of AF, immediate arrhythmia reinitiation occurred in 56% of patients cardioverted within 1 hr of arrhythmia onset but in only 12% of those cardioverted more than 24 hrs after arrhythmia onset (16) . Thus, cardioversion of AF in the intensive care unit should probably be reserved for patients in true hemodynamic collapse or for those in whom rate-control is not feasible and have been already "loaded" with an antiarrhythmic agent.
The present study provides useful clinical information on the incidence and risk factors for the development of AF in surgical intensive care patients. We expect that high-quality clinical research will, in the near future, provide more solid evidence on which to base therapeutic recommendations for this up to now neglected condition. O ver the last 1-2 decades, a large number of therapeutic strategies directed at mediators of initiation and perpetuation of inflammatory-immune system activation in acute lung injury (ALI) have been disappointing. Among the consequences of activated inflammatoryimmune processes is the exuberant production of reactive oxygen, nitrogen, and halogen species (ROS/RNS/RHS), via contributions of phagocytic and potentially nonphagocytic nicotinamide adenine dinucleotide phosphate oxidases, xanthine oxidase, nitric oxide synthases, heme peroxidases, and other oxidantproducing systems (1, 2) . Compelling evidence now documents that oxidative, nitrosative, and halogenative biomolecular "damage" represents a hallmark of inflammatory reactions at nearly all sites of injury (3) including the lung (4, 5) . This suggests that ROS/RNS/RHS-related pathways initiate and/or amplify further tissue injury at these sites. It is thus no surprise that antioxidant therapies have been proposed for many respiratory tract diseases accompanied by inflammation, perhaps most notably cystic fibrosis and adult respiratory distress syndrome (ARDS) (1, 6) but also chronic obstructive pulmonary disease and asthma (7) .
Albumin, the most abundant protein in extracellular fluids, is among the putative important antioxidants present in plasma. The main feature for this property is its single reduced thiol (ϪSH) group that comprises approximately 80% of the total free thiols in plasma. Not surprisingly, as plasma albumin concentrations decrease secondary to decreased hepatic synthesis secondary to acute phase reactions, hemorrhagic and exudative losses, or redistribution from plasma to interstitial fluids as a consequence of increased capillary permeability, plasma protein-SH concentrations decline.
In a 1994 report, Quinlan et al. (8) reported that total plasma protein and protein-SH concentrations were significantly higher in ARDS survivors than in nonsurvivors and that the survivors had increasing protein-SH concentrations as their ARDS resolved, whereas the nonsurvivors had declining protein-SH concentrations (8) . In 1998, this same group of investigators reported that in patients with sepsis syndrome, rapid infusion of 40 g of albumin increased both plasma albumin and protein-SH concentrations and that this was maintained over Ն4 hrs, a time when albumin concentrations were, not surprisingly, shown to be positively correlated with protein-SH concentrations (9) . These two articles emphasized that albumin could be beneficial to the treatment of ARDS and septic patients via its "antioxidant" effects.
Taking their earlier observations a step further, in this tissue of Critical Care Medicine, Dr. Quinlan and colleagues (10) studied ALI patients (mean PaO 2 /FIO 2 ratio, 172 mm Hg) who were randomized to receive 24 g of albumin or an equal volume of normal saline every 8 hrs with furosemide, blood being sampled before and after the first, fourth, and seventh doses of albumin for a variety of both conventional and unique assays. This infused amount of albumin represents approximately 50% of the normal human albumin pool. Assays performed included plasma "total antioxidant capacity," albumin and total protein, protein carbonyls (an indicator of protein and/or lipid oxidation), protein-SH, lipid hydroperoxides, and assays related to iron-binding and iron-mediated oxidant protection. The data presented further cultivate the concept of a positive relationship between albumin and protein-SH concentrations and, not surprisingly, between total antioxidant capacity and albumin concentrations. Small (and likely not statistically significant) decreases in protein carbonyls were seen following albumin administration.
Albumin is suggested to be helpful in the management of ALI via evidence that, when combined with furosemide, it promotes diuresis and affects some variables of clinical outcome by influencing intravascular hydrostatic and oncotic forces, possibly by enhancing net fluid movement out of the edematous lung (11) . As Dr. Quinlan and colleagues (10) acknowledge, albumin is a complex multifaceted protein that, via its variety of electrostatic, hydrophobic, and specific binding domains, accommodates a multitude of trace metal, lipid, peptide, and protein species that can be expected to provide numerous pathophysiologic functions beyond maintaining plasma oncotic pressures. It should be recognized, however, that a meta-analysis of 55 trials involving diverse conditions such as trauma, burns, and other hypoalbuminemic conditions failed to show significant effects of therapeutic albumin infusions on mortality rate (12) .
Dr. Quinlan and colleagues (10) have again provided a theoretical construct for maintaining plasma protein-SH in sepsis/ ARDS/ALI. Although the findings bring us closer to understanding more fully the utility of albumin infusions as a possible therapeutic intervention, there are potential technical glitches regarding the interpretation of the present findings. For instance, no information is provided concerning the protein-SH and carbonyl concentrations of the infused albumin, known to itself contain elevated protein carbonyls, complexed metals, and undocumented/variable amounts of free protein-SH, as previously noted by the investigators (13) . Additionally, there is considerable controversy as to the extent that the plasma total antioxidant assay, which scores the ability of plasma antioxidants to inhibit oxidation of an oxidant-sensitive dye (ABTS) relative to the scavenging mediated by the water-soluble vitamin E analog, Trolox, relates to any meaningful biological/physiologic outcome. This assay is heavily dependent on plasma uric acid, ascorbate, and protein-SH concentrations and thus far has not been shown to provide useful clinical information. A more thorough examination and report of specific plasma antioxidants (and oxidative products) would have been informative in the context of the authors' findings. The assays report-ing plasma "iron-binding antioxidant protection" and "iron-oxidizing antioxidant protection," which are locally used, are likewise of limited clinical use despite the known and probable dysregulation of iron homeostasis in inflamed alveolar spaces (14) . There is also the fact that the interstitial albumin-SH concentrations are presumably elevated and not decreased at the tissue sites of inflammatory lung edema! Finally, it is already well recognized that decreases in albumin reflect mortality and morbidity rates in many intensive care clinical settings, correlating strongly with markers of inflammatory-immune system activation. This is not surprising in that in most of these clinical settings, nutritional intake is suboptimal and liver albumin synthesis is decreased (e.g., albumin is a negatively regulated acute phase reactant).
Despite knowledge concerning many of the mechanisms of ROS/RNS/RHSinduced oxidative stress and the characterization of a plethora of "markers" of their bioactivity, largely acknowledged to be related to the type, intensity, extent, and duration of the inciting inflammatory-immune system activation, there is scant evidence, even in ALI/ARDS (15, 16) , that specific strategies designed to directly counter the accompanying oxidative stress would be clinically efficacious. The value of the current provocative report is considerably enhanced in that it suggests a solid framework for moving the field forward.
First and foremost is the need for standardization and validation of methods used to measure variables of both inflammation and evidence of ROS/RNS/ RHS-related stress, in both lung and plasma compartments. Interrelating them would be a quantum leap forward. Beyond standardization, there are additional challenges including mechanistic studies further characterizing the details of lipid and protein oxidation, including the reversibility, fate, and biological activity of these pathways, including metabolomic and proteomic profiling of the actual species being generated, importantly even addressing the fate of the protein-SH species under current focus (10) ; that is, is albumin-SH oxidation reversible or irreversible? Is it the consequence of oxidant-induced sulphenic/ sulfinic acid formation or adduction by reactive electrophiles produced by lipid or amino acid oxidation (i.e., reactive aldehydes)? We could then begin to unravel whether targeted antioxidant-directed therapies in themselves would be capable of modulating the initiating and ongoing inflammatory-immune process as it relates to clinical outcome. Such approaches are obligatory if the field of oxidative stress is to provide more than simply "biomarkers" of inflammatory oxidative damage and perhaps prognosis (17) (18) (19) .
The utopian goal is ultimately to provide a firm theoretical construct addressing the mechanisms and contribution of oxidative/nitrosative/halogenative tissue damage that can be expected to be favorably ameliorated by targeted antioxidant strategies. Using state-of-the-art technology is of utmost importance as we exit the days of traditional biochemical assays and enter the era of genomics, proteomics, and metabolomics. Until this approach is encouraged and routinely used, we wait in anticipation.
Carroll E. Cross, MD Jason P. Eiserich, PhD Departments of Internal Medicine and Human Physiology University of California, Davis, School of Medicine Electrical impedance tomography: On the path to the Holy Grail* F or almost 30 yrs, clinicians have pursued the proper physiologic variable, derived lung mechanical variable, or monitoring device to guide ventilator management. The calculation of maximal oxygen delivery, the estimation of the lower inflection point on the inspiratory pressure-volume curve, or, more recently, the shape of the pressure-time profile (1) have all been served up as offering the essential window on the optimization of lung volume.
The quest for the Holy Grail of optimized lung volume has been greatly accelerated by the clear demonstration that the lung is an active participant in the multiple-organ failure sequence (2). Lung-protective ventilation not only prevents the progression of lung injury but also greatly reduces the release of inflammatory cytokines from the lung parenchyma itself, which are directly related to collateral organ injury. There is now convincing evidence that ventilator strategy directly alters systemic release of cytokines from the lung (3) and can influence such important intensive care outcomes as mortality (4) . Clinicians have now heard the convincing call to optimize lung recruitment, maintain an open lung, and limit lung overdistension.
On the other hand, we have known since the mid 1980s that acute lung injury is a heterogeneous disease (5). We also know that acute lung injury produces a marked heterogeneity of lung mechanical properties that produces distinct regional differences in opening/ closing pressures (6) . It is now clear that a description of mean lung behavior is not precise enough to allow lung protection to be provided to both dependent and nondependent lung regions using conventional technologies. We need to move beyond a description of mean lung behavior and quantify the regional differences in lung mechanics that are present in acute lung injury.
Electrical impedance tomography (EIT) uses the variability in electrical impedance between tissue, air, and fluid to provide a "map" of impedance changes. Surface electrodes are applied circumferentially around the organ of interest, and each electrode sequentially transmits and receives an electrical microcurrent. The variability in electrical conductivity in the organ of interest is expressed as a two-dimensional map of impedance change that provides important anatomical information. The technology is Ն30 yrs old and has been used in such widely varying applications as breast imaging and cancer detection, quantification of gastric emptying, assessment of pulmonary perfusion and pulmonary edema formation, and cerebral ischemia (7) .
Recently, a number of investigators have focused on EIT applications in pulmonary imaging. Adler et al. (8) used a custom EIT system and back-projection reconstruction to generate dynamic images of impedance change in an uninjured animal lung. EIT was able to accurately describe lung volume changes during incremental increases in gas volume, during conventional mechanical ventilation, and during the intrapulmonary instillation of an albumin solution. Kunst et al. (9) used a slightly different EIT device to describe regional impedance changes in a saline lavaged lung injury model. EIT-derived impedance changes correlated very closely with whole lung pressure-volume relationships quantified by strain gauge plethysmography. The investigators noted marked differences in the pressurevolume characteristics between the anterior and posterior aspects of the lung. The same group of investigators subsequently described the ratio of anteroposterior lung impedance changes during recruitment and derecruitment in the same animal model (10) . Although the data generated by this study were primarily descriptive, the potential of EIT to provide dynamic, noninvasive information about differences in regional lung behavior was clear.
More recently, a separate group of investigators has used their own EIT system to validate regional lung volume measurements in a normal lung model (11) . Ventilator-induced changes in regional air content were quantified using off-line analysis and a modified version of the filtered back-projection algorithm. The change in local lung air content measured by this system correlated quite closely with simultaneous electron beam computed tomography measurements (r 2 ϭ .69 -.86). The significance of this study is that regional (not global) changes in lung impedance were compared with an established reference method (electron beam computed tomography). Most recently, yet another group has developed a functioning EIT system and, for the first time in humans, provided validation of regional lung volume change with simultaneous computed tomography scans during mechanical ventilation (12) .
In this issue of Critical Care Medicine, Dr. van Genderingen and colleagues (13) explore the further application of this exciting technology during high-frequency oscillatory ventilation (HFOV) in an animal model of lung injury. Animals underwent repetitive saline lavage to achieve the same physiologic end point (PaO 2 Ͻ80 mm Hg). A 16-electrode EIT system was used to describe global and regional impedance changes during an inflationdeflation maneuver using a super syringe technique. Reference methods to which EIT-derived lung volume measurements were compared included helium dilution (end-expiratory volume) and strain gauge plethysmography (lung volume change). The animals were then converted to HFOV, and regional impedance changes during incremental increases and decreases in mean airway pressure were computed. Changes in regional impedance were assumed to correspond to changes in regional lung volume, an assumption strengthened by previous validation of the device used in this study (11) .
The principal findings of this study were that a) regional heterogeneity in impedance changes during the inspiratory super syringe maneuver, which was not seen during deflation; and b) relative regional homogeneity in impedance changes during progressive increases and decreases in mean airway pressure during HFOV. As with all experimental studies, perfection was not achieved. The differences between methods of lung volume measurement at the end of the experiment were marked. The authors suggest that the accumulation of intrathoracic fluid may explain these differences, but this is mostly speculation. Furthermore, the lung volume at a mean airway pressure of 40 cm H 2 O during HFOV was approximately 20% higher than the lung volume at 40 cm H 2 O airway pressure during the static inflation maneuver. The authors suggest that HFOV may produce a lung recruitment effect by opening "sticky airways." This is an interesting but unproven hypothesis that has not previously been described. An alternative conclusion is that HFOV introduces a measurement error that has not been accounted for. This HFOV-related measurement error may also explain the differences in degree of regional heterogeneity observed during static inflation with the super syringe, which were not evident during recruitment with HFOV.
Despite these shortcomings, this study is the first to describe the utility of EIT during HFOV, which is a rapidly emerging innovation in managing acute lung injury (14, 15) . Further experience with these two technologies will follow; the ultimate goal will be to demonstrate that optimization of regional impedance changes results in improved histopathologic outcomes in models of lung injury.
Let's return to the title of the editorial and tackle questions that have preoccupied generations of theologians, knights errant, and clerics. What exactly is the Holy Grail? Is the Holy Grail a chalice (or device) that allows divine insight regarding centuries of Judeo-Christian history? Is the Holy Grail a person (a group of investigators) who will point out the true path to enlightenment? Or is the Holy Grail a state of mind (a scientific process) that allows us to abandon outdated modes of inquiry and focus on the proper questions that will bring us closer to optimizing lung protection during mechanical ventilation? Electrical impedance tomography will force us to understand the regional heterogeneity in lung behavior that is accentuated by acute lung injury and tailor supportive mechanical ventilation to provide lung protection for the entire lung. Aggressive volume recruitment appears to improve lung mechanics and reverse alveolar densities in dependent lung; however, it is also likely that aggressive lung opening creates lung overdistension and pathologic lung stretch in the more compliant nondependent lung.
At present, EIT technology is not perfect. The mapping of complicated threedimensional structures with periodic motion artifacts (cardiac contraction and respiratory cycling) on a two-dimensional template is problematic. The resolution of current devices is roughly 10%, which is not precise enough to replace more conventional imaging techniques such as computed tomography or magnetic resonance imaging. However, an on-line dynamic monitor that is noninvasive, radiation free, and portable to the bedside offers significant advances over other monitoring technologies. It is hoped that the regional information provided will transform our formulation of the lung as one large organ and provide sang real insight that will deliver true lung protection. As we look to the future, our understanding of the pathophysiology of acute lung injury and ventilator-associated lung injury will no longer be forced to accommodate itself to the shortcomings of our technology.
John The inflammatory response to injury or infection is initiated and coordinated through the signal network of cytokines and other inflammatory mediators (IMs). At the system level, inflammation operates as a complex, dynamic control system ensuring inflammatory activity proportionate to the stimulus (1). This complexity results from several characteristics. Positive feedback loops and synergistic interaction of different IMs provide nonlinear amplification of inflammation (2) . Redundancy and pleiotropy among IMs provide a network that still operates effectively even if some particular component is blocked (3) . Under the tenets of systems biology, a drug directed at some "key" IM or subsystem would be bypassed by other, redundant and pleiotropic IM pathways, and system activity would be restored by dynamic amplification loops. Thus, a drug would not be expected to control inflammation at the system level. These characteristics may be the principal reasons why attempts to develop a sepsis drug have possibly the worst failure rate in the pharmaceutical industry (4) .
System control theory, commonly used by engineers to design and regulate complex systems, is increasingly recognized as critical to understanding complex biological systems (5). The tenets of control theory indicate that control of inflammation would require reduction in the activity of some minimal number of IM signal pathways. The more pathways controlled, the better overall regulation of the system. Membrane separation (hemofiltration, plasma filtration), centrifugal (plasma separation), or adsorptive mechanisms offer techniques that can nonspecifically remove a wide spectrum of IMs from blood.
As reported in this issue of Critical Care Medicine, Dr. Kellum and colleagues (6) evaluated adsorption as a method to remove several IMs and control inflammation. They used a murine model of acute, lethal endotoxemia to evaluate the effects of a novel adsorptive cartridge (CytoSorb, RenalTech) on clinical, physiologic, and biochemical outcomes. The study was well done, revealed a number of findings of interest, but should be interpreted with caution.
The problem with the study is the acute administration of a lethal dose of endotoxin to previously healthy animals resulting in a disease course of Ͻ12 hrs. This type of model has little resemblance to most human sepsis, which occurs in patients previously seriously ill or injured, often for many days, and with sepsis evolving over variable periods ranging from hours to days. Failed sepsis drug trials have been attributed, in part, to initial drug evaluation in models of this type (7) . Despite this limitation, several findings of great interest were reported.
Perhaps the most important finding was the significant reduction in the expression of nuclear factor-B DNA associated with 4 hrs of hemoadsorption. A major criticism of all blood filtration or separation methods in sepsis is that they can only affect IMs circulating in blood. These circulating IMs are considered the "tip of the iceberg," with IMs of pathologic significance being active at the tissue level (8, 9) . However, cytokines rapidly traffic between blood and tissue. Intact 125 I-interleukin (IL)-1␣ injected centrally in mouse brain exits with a half-life of 21.0 mins, more rapidly than can explained by resorption of cerebrospinal fluid (10) . Similar rapid effusion from central nervous system is observed with tumor necrosis factor (TNF) and IL-2 (11). Cytokine trafficking also occurs across Descemet's membrane (12) and vascular interfaces with spinal cord, testis, and muscle (13) . Depletion of IM plasma pools may result in kinetic reduction in tissue IMs. Although hemofiltration has improved survival in both clinical and animal sepsis, these improvements have been attributed to "improved metabolic control" or mechanisms other than control of inflammation (9) . Dr. Kellum and colleagues (6) have demonstrated that depletion of plasma IMs can specifically abate inflammatory activity at the tissue level.
The authors state, "The effects of hemofiltration on the inflammatory response are predominantly the result of adsorption [of IM] to the filter membrane" (6) . Goldfarb and Golper (14) studied adsorption of TNF and IL-1 in six different filters of four different materials. TNF was adsorbed by two of six and IL-1 by four of six membranes; only one membrane adsorbed both. Of available CK mass, TNF was adsorbed ‫%03ف‬ in two membranes and IL-1 Յ3.3% in four membranes. Dr. Kellum and colleagues (6) report significant reductions in plasma IL-6 and IL-10 by the CytoSorb but no significant effects on plasma TNF. Thus, adsorption is extremely variable between materials and typically low in HF membranes. Attributing IM removal in hemofiltration "predominantly" to adsorption is not supported. Lee et al. (15) used a swine model of lethal Staphylococcus aureus sepsis to conduct paired comparisons (sham filtered vs. active filtration) of a polysulfone (Renal Systems HF250) hemofilter across three groups of different filtration fraction. Ultrafiltrate was collected, concentrated by cascade filtration, and reinfused into healthy pigs. Reinfused ultrafiltrate was sterile and lethal, causing a clinical and pathologic disease similar to S. aureus bacteremia. As filtration fraction increased (5.5, 16.6, and 33.4%), percent increment in survival time increased in each group (57, 97, and 312%, respectively). Survival time in ultrafiltrate recipient pigs also increased with filtration fraction. These findings suggest increasing adsorption and less sieving with increasing filtration fraction.
Given the substantial variability in adsorption between materials, and with different operating variables, it seems premature to identify a predominant mechanism of IM removal. Studies of membrane or depth filters in sepsis should stipulate materials, surface area, and operating variables, as all appear to have effects on filtration efficacy and the balance of mechanisms of IM removal. This acute endotoxin model, truncated at 12 hrs, makes survival time and survival difficult to evaluate. Survival time increased by 21%, which is less than the 57-312% increases in survival time seen with hemofiltration (15) . Relative reduction in mortality rate calculated from the authors' data is 31.6%. This is encouraging but is equaled or surpassed by relative reduction in mortality rate calculated from dose-adjusted clinical studies, for example, 31.9% by Ronco et al. (16) and 82% by Honore et al. (17) .
Dr. Kellum and colleagues (6) have provided important new insights. First, they have shown that reduction of plasma cytokine activity is associated with reduced nuclear factor-B DNA binding activity. This indicates that hemo-or plasma filtration methods can significantly affect tissue inflammatory activity. Second, the novel adsorptive device evaluated appears to have modest effects compared with membrane separation methods. However, it and other devices that have the potential of controlling septic inflammation at the system level warrant further, disciplined evaluation. However, a number of important issues relating to this therapy still require clarification. For example, should patients with an initial cardiac rhythm other than ventricular fibrillation also be cooled? In particular, pediatric and young adult patients usually suffer cardiac arrest as a result of asphyxia due to neardrowning, hanging, or severe asthma. In these patients, severe cerebral edema may occur (4), and although hypothermia is known to decrease intracranial pressure after head injury (5), earlier reports of the use of hypothermia in children after near-drowning were not encouraging (6) . In adults with asystolic cardiac arrest, good outcome is very rare (7) . Would the use of hypothermia only lead to some additional survivors with severe disability? Also, what should be the duration of hypothermia? In laboratory studies in dogs, hypothermia was used only for 1 hr (8, 9) , whereas the clinical trials used 12-24 hrs (2, 3) . Finally, and perhaps most importantly, what technique should be used to quickly, easily, and safely induce hypothermia after cardiac arrest?
Laboratory evidence suggests that the earlier hypothermia is applied, the better the neurologic outcome (8, 9) . However, current techniques of surface cooling are problematic, and this may be a major factor that has delayed the widespread use of this treatment. In the Australian study, patients received neuromuscular blockade, and ice packs were then applied over the head, neck, and trunk (2) . Although relatively simple and inexpensive, this approach is cumbersome, inconvenient, and unpopular with medical and nursing staff. In the European study, refrigerated air blankets were placed above and below the patient (3). This provided for even slower cooling and restricted access to the patient for procedures. Cold water blankets (10) and cooling helmets (11) have been studied and also found to lower core temperature slowly. Although evaporative cooling increases the rate of heat loss, this technique is time-consuming and raises infection control issues with the use of fans in the intensive care unit.
In any case, since cardiac arrest patients generally have poor peripheral perfusion, improved technologies in surface cooling are likely to have limited impact. Therefore, core cooling would be preferred, but this presents additional difficulties. The use of intravascular cooling devices has been reported in stroke patients (12) and in myocardial infarction patients undergoing coronary artery intervention (13) . Although effective in lowering core temperature quickly, these devices are expensive and require appropriate physician training for insertion. Cardiopulmonary bypass and heat exchange have been used (14) but are not feasible for most centers. Recently, we have used a rapid infusion of largevolume (30 mL/kg), ice-cold (4°C) saline with encouraging results (15) . This would be feasible for use by emergency medical service paramedics, and a clinical trial using this approach is being undertaken in Melbourne, Australia. Other novel approaches at an experimental stage include the use of intragastric "cold slush" (L. Becker, personal communication, February 2004) and partial liquid ventilation with ice-cold perfluorocarbons (16) .
In this issue, Dr. Katz and colleagues (17) describe a pharmacologic approach to core cooling after cardiac arrest. The authors used a neurotensin analog (NT77) to induce core cooling in rats. As explained by the authors, neurotensin concentrations have been shown to be elevated during hibernation. One primary effect of neurotensin in the brain is thermoregulation, and this endogenous tridecapeptide has specific receptors throughout the central nervous system of mammals, including rats and humans. This compound induces a hibernationlike state in rats in which core temperature decreases to 33°C for some hours. The asphyxial cardiac arrest model for the study involved the administration of a muscle relaxant and ventilator disconnection. This resulted in cardiac arrest after 4 mins, which was untreated for a further 4 mins, followed by resuscitation. The four treatment groups consisted of normothermic controls, brief (4-hr) surface cooling, prolonged (24-hr) surface cooling, and brief (4-hr) core cooling using NT77. The study found that functional recovery in all groups was similar at 15 days postarrest; however, the percentage of ischemic neuronal damage in the prolonged cooling group and the NT77 group was significantly less than in both the brief cooling and the normothermic control group. Although much more research is required before this compound is considered for human use, the concept that core temperature might be lowered pharmacologically is an interesting new approach to this problem.
Also of considerable interest is the comparison between the two surface cooling treatments in this report. The study found that prolonged (24-hr) hypothermia is associated with improved histologic outcomes compared with brief (4-hr) hypothermia. This, as well as other data (18), supports the concept that prolonged rather than brief hypothermia is required after asphyxial cardiac arrest.
How should clinicians induce hypothermia? A reasonable approach for patients who are unconscious after resuscitation from cardiac arrest would be to administer a muscle-relaxant followed by a rapid infusion of 30 mL/kg ice-cold lactated Ringer's solution. To avoid any rebound increase in temperature, or where the administration of fluid is limited by pulmonary edema, surface cooling with ice packs should then be undertaken, as needed, to further lower core temperature to 33°C. Hypothermia should be maintained for Ն12 hrs after ventricular fibrillation cardiac arrest; however, the available laboratory evidence seems to support a recommendation that hypothermia be maintained for Ն24 hrs if the cardiac arrest was due to asphyxia.
Stephen Is pulmonary edema associated with a high extravascular thermal volume?* I mpaired gas exchange, reduced pulmonary compliance, and pulmonary consolidations on chest radiography are, either alone or together, relatively poor indicators of the amount and course of pulmonary edema of various etiologies (1, 2) . Direct measurement of lung vascular injury and lung edema should facilitate therapeutic clinical trials to evaluate new drugs effective in animal models of acute respiratory distress syndrome (ARDS).
The only noninvasive, nondestructive bedside method to directly assess the amount of extravascular lung water (EVLW) as a measure of pulmonary edema in the critically ill is the assessment of extravascular thermal volume (ETV) with the help of a double, transpulmonary indicator dilution technique, involving a dye and cold dextrose, central venous bolus injection and detection in the aorta via a femoral artery catheter of the respective dilution curves (2). The differences in dilution curves between the intravascular dye and the cold, of which some dissipates into the pulmonary structures, dependent on their hydration status, yield a thermal distribution volume as a rough indicator of EVLWpulmonary edema. The technique (Edwards Laboratories, CA) uses the femoral artery catheter to withdraw blood at a constant rate for ex vivo determination of dye density with a densitometer. The thermal signal is detected intravascularly. Using a lung water computer, dye and thermal dilution curves are compared, at a similar starting point. The difference in mean transit time multiplied by cardiac output yields the ETV in the thorax, as a measure of EVLW. Using the Edwards densitometer technique, Mihm et al. (3) and others already noted that the EVLW (ETV) overestimated gravimetric EVLW at a postmortem examination, the gold standard, in dogs and human organ donors, regardless of the cause of edema, that is, hydrostatic forces or increased permeability (4, 5) . Nevertheless, the correlation between the two, over a wide range of volumes, was high (3) (4) (5) . Indeed, (fluid) therapy based on this EVLW rather than on a pulmonary artery occlusion pressure after pulmonary artery catheterization was associated, in critically ill patients, with acute lung injury and pulmonary edema, with an increase in ventilator-free days and decreased morbidity rate (6). The thermal-dye EVLW method never gained wide popularity, partially because of its laborious nature. There are new developments in the methods and views on the utility of in vivo EVLW measurements in the critically ill ( Table 1) .
The technique was revived in the 1990s by a German company, using a similar approach with a fiberoptic and thermistor-equipped 4-Fr femoral artery catheter and thermal-dye dilution, to assess the EVLW (7). The technique involves the intravascular determination of the dye and the thermal signal (COLD machine Z-021, Pulsion Medical Systems, München, Germany) (7) after central venous injection (8) . The mean transit time of the dye (detected in the aorta via femoral artery catheter) multiplied by cardiac output yields the intrathoracic blood volume, whereas the mean transit time of the thermal signal multiplied by cardiac output yields the intrathoracic thermal volume. Subtracting the volumes gives the EVLW (in mL/kg, upper normal values about 7 mL/kg) (7). A recent paper using this new technique indeed confirmed the prognostically adverse effect of a high EVLW, regardless of the severity of underlying disease, in the critically ill who had sepsis, ARDS, or other conditions (8). The transpulmonary technique allows for assessment of not only EVLW Table 1 . Clinical applications to be explored of a new thermal-dye dilution technique to assess extravascular lung water Differentiation between permeability edema (ALI/ARDS) and hydrostatic/cardiogenic pulmonary edema Monitoring tool during fluid resuscitation for hypovolemia and shock Monitoring tool during preload reduction and forced diuresis/ultrafiltration in the treatment of pulmonary edema Monitoring tool for drug studies promoting resorption of pulmonary edema Assessing effect of new drug therapies for (indirect) ALI/ARDS Assessing lung-protecting ventilator strategies ALI, acute lung injury; ARDS, acute respiratory distress syndrome. but also intrathoracic blood volumes and cardiac output, without the use a pulmonary artery catheter.
A modification of the transpulmonary technique with detection in the femoral artery, recently marketed (PiCCO, Pulsion Medical Systems), is the single thermodilution technique for EVLW * estimation, using a constant relation between global end-diastolic volume estimated from the difference of intrathoracic thermal volume and the pulmonary thermal volume, calculated from the thermal dilution down slope times cardiac output, and the intrathoracic blood volume, so that intrathoracic blood volume equals 1.25 times global end-diastolic volume Ϫ28.4 mL, at least in humans (9) . The difference between the intrathoracic thermal volume, estimated from the mean transit time of the thermal signal times cardiac output, and the intrathoracic blood volume estimated previously is the EVLW * (9). The latter technique might simplify the thermal-dye technique and suffice to judge EVLW for clinical purposes. This certainly needs further evaluation, however, although first evaluations suggest a good correlation between single thermal and thermal-dye dilutional EVLW (9) . Another variable evolving is the permeability index, the ratio of EVLW * to pulmonary blood volume. Pulmonary blood volume is determined from the difference between pulmonary thermal volume (intrathoracic thermal volume minus global enddiastolic volume) and EVLW * . Indeed, congestive heart failure leading to an increase in pulmonary blood volume and edema is expected to increase the ratio less than an increase in permeability in the course of acute lung injury or ARDS. Definite human data confirming this concept are still lacking (10) . When combined with pulmonary blood volume, assessment of EVLW nevertheless could help to differentiate among edema types, that is, mainly hydrostatic vs. predominant permeability edema. The utility of this concept also needs further evaluation.
Despite its potential, there are some drawbacks of the dilution method, inherent to the technique, and some questions remain as to the effect of cardiac output and hypoperfusion of edematous areas on the measurement. Indeed, the method may not pick up the distribution volume of the temperature indicator in areas that are underperfused. Obstructing pulmonary arteries in a pig model, mimicking pulmonary arterial embolization, lowered thermal-dye EVLW (11) . Also, a high cardiac output may lead to underestimating EVLW, by impairing time for thermal diffusion, and positive end-expiratory pressure may increase the distribution of the thermal indicator and increase EVLW, although this is controversial and opposite observations have been made, dependent on the technique used (3, 7, 12) . Indeed, the fiberoptic technique may be less prone to errors inducing cardiac outputdependency of EVLW than the densitometer technique (7) . Thermal loss may affect both cardiac output when determined from the thermodilution curve and the ETV (3). Boldt et al. (13) , however, observed that altering cardiac output after cardiac surgery in humans did not affect the thermal-dye EVLW (densitometer technique). Indeed, an increase in cardiac output itself should not alter pulmonary edema, even during permeability edema, since the edema is mainly governed by transcapillary pulmonary pressures, interstitial compliance, and alveolar resorption.
Edema that is poorly perfused is poorly reflected by the thermal-dye technique, so that some types of edema are less well reflected by EVWL measurements than others. This has been demonstrated in prior animal studies as well as in the current issue of Critical Care Medicine by Dr. Roch and colleagues (12, 14 -16) . Carlile et al. (12, 14, 15) , using the densitometer technique, already noted that hydrochloric acid aspiration in dogs increased gravimetric pulmonary edema more than the thermal-dye EVLW, so that ETV underestimated EVLW, whereas alloxan, oleic acid, or ␣-naphthylthiourea-induced pulmonary edema increased both thermal-dye and gravimetric EVLW to a similar extent. Unilateral hydrochloric acid injury, in particular, increased gravimetric more than thermal-dye ELVW (14, 15) . Of concern in the article by Dr. Roch and colleagues (16) , using the new fiberoptic method (Pulsion Medical Systems), is that the thermal-dye dilution technique was not able to pick up an increased (Ͼ7 mL/kg) EVLW in 65% of animals with gravimetrically determined pulmonary edema after intrapulmonary hydrochloric acid instillation, even though thermal-dye EVLW increased over baseline. Interestingly, the authors observed an underestimation of gravimetric by thermal-dye EVLW, not only in experimental but also in control conditions. It is unclear why this discrepancy is at variance with some other literature and what the major source of error is (3) (4) (5) . In contrast to hydrochloric acidinduced pulmonary edema, thermal dye-EVLW during edema induced by oleic acid nevertheless highly correlated with gravimetric EVLW. Obviously, a clinical counterpart of these observations would be difficult to obtain, unless EVLW measurements in vivo are done soon before or after a postmortem gravimetric study (4) , the ultimate gold standard. Nevertheless, the system is expected to better reflect the degree of edema during acute lung injury/ARDS, caused by indirect injury, including sepsis, than that caused by direct/inhalational injury. Issues that remain unresolved include the time constant for changes in EVLW on changes in pulmonary occlusion pressure, the value in decision making, and morbidity and mortality rates of the critically ill, despite some information in prior animal models (3, 5, 10, 12, 15) . Indeed, there are no new diagnostic therapeutic studies aimed at preventing or ameliorating an increase in EVLW and subsequent morbidity and mortality rates, thereby confirming and extending the Mitchell et al. study (6) .
The answer to the question posed in the title to this editorial is thus yes-but with limitations. The Endothelial cell apoptosis in sepsis: A case of habeas corpus?* T he role of endothelial cells in the pathophysiology of sepsis has received increased attention since the publication of studies showing that activated protein C can improve survival in selected patients with sepsis. A recurring theme in sepsis research has been that the endothelial cells can drive the inflammatory response by release of procoagulant and proinflammatory molecules. It is now clear that there is "cross-talk" between the coagulation and inflammatory cascades. Thus, prevention of endothelial injury and the resultant intravascular coagulation may modulate the production of proinflammatory cytokines and chemokines.
Based on this hypothesis, investigators have examined endothelial injury and death using various models of sepsis and infection. Numerous studies have demonstrated that endothelial cells undergo apoptosis in response to a host of stimuli including serum growth factor withdrawal, Fas activation, and radiation injury (1) (2) (3) (4) . Apoptosis of endothelial cells also has been reported in regions of atherosclerotic plaques. Considered together, these studies show that endothelial cells are capable of undergoing apoptosis in response to certain stimuli. Similarly, in vitro infectious models demonstrated that certain organisms induce endothelial cell apoptosis. Haemophilus somnus, a common cause of pneumonia and vasculitis in cattle, causes apoptosis in bovine endothelial cells in vitro (5) . Staphylococcus aureus can be ingested by human umbilical vein endothelial cells, and uptake of the bacteria induces apoptosis in the infected cells (6) .
Despite these studies, other investigators have shown that endothelial cells are resistant to apoptosis due to lipopolysaccharide and other stimuli (7, 8) . Some investigators believe that endothelial cells are relatively resistant to apoptotic stimuli (9) . Although there is no clear explanation for the different findings in the various studies, similar discrepancies regarding the effects of apoptosis in in vitro systems have been reported by different groups. Khwaja (10) argued that the different findings regarding susceptibility of cells to apoptotic stimuli may be due to the fact that different cell lines have developed individual molecular quirks that maintain their immortality. Furthermore, he encouraged investigators to shift to the study of networks that control apoptosis in primary tissues (10) .
The only in vivo study of endothelial cell apoptosis is an in vivo mouse model which reported that lipopolysaccharide from Salmonella typhimurium induced disseminated endothelial cell apoptosis in a process mediated via ceramide generation (11) . However, this report has yet to be confirmed, and a number of methodological problems exist with this study. CD31, used in this study as a marker for endothelial cells, is also expressed on monocytes, granulocytes, and lymphocytes. Thus, many of the cells reported as being apoptotic may have been lymphocytes, which may undergo apoptosis after endotoxin exposure. Furthermore, the authors used the terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick-end labeling (TUNEL) method as the sole means to identify apoptosis in endothelial cells. This is problematic because, as noted by numerous investigators, the TUNEL method lacks specificity and may be falsely positive in certain types of cells (12) . In summary, the findings suggesting that lipopolysaccharide induces endothelial cell apoptosis are not conclusive and require confirmation.
There are enormous challenges in attempting to examine endothelial cell apoptosis using in vivo models. Part of the reason why it may be so difficult to document endothelial apoptosis is that endothelial cells detach from the basement membrane very early in the apoptotic process. The dying endothelial cells enter the circulation and are rapidly cleared.
Our laboratory searched for apoptotic endothelial cells in a rat cecal ligation and puncture model using electron microscopy of aortic vessel wall 24 hrs after cecal ligation and puncture. We did not detect any apoptotic cells. We also were unable to find endothelial cell apoptosis in vascular samples from patients who died of sepsis. It is possible that endothelial cell apoptosis occurred but the cells had detached and been cleared from the circulation. In a study of Pseudomonas aeruginosa pneumonia, our laboratory did observe rare caspase 3 positive capillary endothelial cells in lungs from mice with pneumonia but not sham-treated mice (13) . However, capillary endothelial apoptosis was an extremely infrequent event.
In this issue of Critical Care Medicine, Dr. Janiszewski and colleagues (14) nicely document the presence of circulating platelet-derived microparticles in blood from patients with sepsis. Circulating microparticles have been demonstrated to have major effects on endothelial cell function in myocardial ischemia, trauma, and sepsis (15, 16) . Thus, their finding may have important implications in sepsis. The authors also report that the microparticles enhanced endothelial and smooth muscle cell apoptosis in vitro and the effect was mediated by reactive oxygen species. Apoptosis was detected by fluorescence microscopy and annexin V staining. Unfortunately, no other method was used to confirm apoptotic cell death, and annexin V suffers from a lack of specificity. Also, this in vitro study does not really address the issue of whether endothelial cell death is important in vivo.
In summary, although endothelial apoptosis may be an important event in sepsis, a writ of habeas corpus has been issued and the defendant says, "Show me the body." Studies are underway to generate transgenic mice whose endothelial cells express anti-apoptotic molecules (J. Harlan, personal communication), and these models will be critical in determining the true role of endothelial cell death in sepsis.
Richard S. Hotchkiss, MD Irene E. Karl, PhD Washington University School of Medicine St. Louis, MO
The golden day after subarachnoid hemorrhage* S ubarachnoid hemorrhage (SAH) is a life-threatening critical neurologic illness, most often caused by a ruptured aneurysm that requires rapid diagnosis and critical care. The critical care of SAH is sequential, starting with hemodynamic and airway stabilization, and it progresses in a stepwise fashion to the diagnosis of aneurysmal bleed by computerized tomography and angiography, occlusion of the aneurysm, treatment of hydrocephalus, treatment of pulmonary and cardiac complications, diagnosis and treatment of vasospasm (1) . This stepwise treatment paradigm requires a multidisciplinary critical care approach.
During the last 20 yrs, attention has been focused on immediate diagnosis and treatment of the bleeding aneurysm within the first 24 hrs. This trend stems mainly from the second international cooperative study on the timing of aneurysm surgery trial (2, 3) . In this seminal study, the rate of early rebleeding within 24 hrs was 4.1%, with a declining rate after day 1. The result of rebleeding is death or increased neurologic disability. With early surgery, Ͼ57% of patients made a good outcome, and mortality was 26% (4). Thus,
